Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 TCR T-cells in Ovarian Cancer
NCT01567891Phase 2Completed
- Sponsor
- Adaptimmune Therapeutics
- Start
- Jul 2013
- Primary completion
- Jun 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of letetresgene autoleucel in ovarian cancer, sponsored by Adaptimmune Therapeutics. Started Jul 2013; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01567891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01567891.